The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a strategic global research collaboration and licensing agreement with Eli Lilly ...

Eli Lilly is currently conducting clinical trials ... phase 1 trials in the U.S., aiming to enter phase 2 next year. The Korea Advanced Institute of Science and Technology (KAIST) announced ...